Syndax Pharmaceuticals (SNDX) Current Deferred Revenue (2015 - 2021)

Syndax Pharmaceuticals' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $12.4 million for Q3 2021.

• On a quarterly basis, Current Deferred Revenue rose 717.4% year-over-year to $12.4 million in Q3 2021; TTM through Sep 2021 was $12.4 million, a 717.4% increase from a year earlier, with the FY2020 full-year figure at $1.5 million, changed 0.0% from the prior year.
• Current Deferred Revenue improved to $12.4 million in Q3 2021 per SNDX's latest filing, from $1.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $12.4 million in Q3 2021 and bottomed at $1.2 million in Q1 2017.
• The 5-year median for Current Deferred Revenue is $1.5 million (2018), against an average of $2.0 million.
• Across the five-year window, Current Deferred Revenue dropped 3.56% in 2018 and soared 717.4% in 2021, its largest moves.
• Year by year, Current Deferred Revenue stood at $1.6 million in 2017, then retreated by 3.56% to $1.5 million in 2018, then changed by 0.0% to $1.5 million in 2019, then changed by 0.0% to $1.5 million in 2020, then surged by 717.4% to $12.4 million in 2021.
• Per Business Quant, the three latest SNDX Current Deferred Revenue figures stand at $12.4 million (Q3 2021), $1.5 million (Q2 2021), and $1.5 million (Q1 2021).